TABLE 3.
Clinical outcomes, stratified by MDC status
| References | Definition early-stage HCC | Early-stage HCC diagnosis | Curative therapy receipta | Time-to-treatment initiation | Factors adjusted in survival analysis | Overall survival |
|---|---|---|---|---|---|---|
| Chang et al21 | TNM stage I/II | MDC: 75/121 No MDC: 14/62 |
MDC: 23/121 No MDC: 4/62 |
NR | None | OR = 7.10 (95% CI: 3.46–14.5) |
| Yopp et al22 | BCLC stage A | MDC: 45/105 No MDC: 65/250 |
MDC: 22/105 No MDC: 24/250 |
Mean 2.3 vs. 5.3 (p = 0.002) | Tumor stage, HCC treatment | HR = 0.40 (95% CI: 0.33–0.49) |
| Kani et al23 | BCLC stage A | NR | Transplant: OR = 1.11, p = 0.79 Resection: OR = 1.06, p = 0.63 |
NR | None | Mean 11.1 vs. 7.4 mo (p = 0.01) |
| Chirikov et al24 | TNM stage I | MDC: 279/811 No MDC: 508/1434 |
NA | NR | Demographics, comorbidities, liver etiology, tumor stage, HCC treatment | HR = 0.86 (95% CI: 0.78–0.95)a |
| Davison25 | BCLC stage A | NR | MDC: 20.9% No MDC: 18.6% |
NR | None | Median 15.1 vs. 6.3 mo (p = 0.2) |
| Vora26 | Milan criteria | NR | Transplant: OR = 2.51, p = 0.002 | NR | None | No difference 1-y overall survival |
| Agarwal et al27 | Milan criteria | MDC: 147/306 No MDC: 90/349 |
MDC: 218/306 No MDC: 152/349 |
NR | Demographics, liver disease severity, AFP level, tumor stage, HCC treatment | HR = 0.72 (95% CI: 0.55–0.95) |
| Serper et al28 | BCLC stage A | NR | Any treatment: OR = 1.19 (95% CI: 0.98–1.46) | NR | Demographics, comorbidities, liver disease severity, tumor stage, HCC treatment, region | HR = 0.83 (95% CI: 0.77–0.90) |
| Diaz et al29 | BCLC stage A | MDC: 95/165 No MDC: 20/62 |
NR | No difference | None | Median 23.4 vs. 8.6 mo (p < 0.01) |
| Duininck et al30 | BCLC stage A | MDC: 24/134 No MDC: 4/70 |
MDC: 5/134 No MDC: 0/70 |
NR | Demographics, tumor stage, HCC treatment | HR = 0.62 (95% CI: 0.40–0.98) |
| Sinn et al31 | BCLC stage A | MDC: 523/738 No MDC: 3513/5881 |
MDC: 241/738 No MDC: 2001/5881 |
NR | Demographics, liver etiology, liver disease severity, tumor stage, AFP and DCP levels, HCC treatment | HR = 0.47 (95% CI: 0.41–0.53) |
| Ehab et al32 | Not defined | NR | NR | Median 17 vs. 24 d (p < 0.01) | NA | NR |
a
Calculated from p-value reported in manuscript.
Abbreviations: AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; DCP, des-gamma carboxy-prothrombin; MDC, multidisciplinary care; NA, not applicable; NR, not reported.